|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
5
|
6586
|
April 11, 2024
|
|
Case-Cohort Design - longitudinal ordinal outcome with interval-censoring
|
|
2
|
142
|
April 11, 2024
|
|
Counterfactual Prediction + Longtitudinal Ordinal Models + Decision Making
|
|
7
|
969
|
April 11, 2024
|
|
Overlap weights for small sample RCTs
|
|
18
|
494
|
April 11, 2024
|
|
ML Approaches with censored data
|
|
3
|
149
|
April 11, 2024
|
|
RMS Ordinal Regression for Continuous Y
|
|
70
|
24049
|
April 10, 2024
|
|
Double Counting in Meta-Analysis
|
|
3
|
179
|
April 10, 2024
|
|
Hybrid AI & Delphi Based Derivation of RCT and Bedside Measurements
|
|
10
|
511
|
April 10, 2024
|
|
Sample size calculation for metabolomic profiles in a nested case-control study
|
|
0
|
160
|
April 8, 2024
|
|
Use of percentage change in clinical trials
|
|
16
|
685
|
April 8, 2024
|
|
When is it clinically reasonable to assume transportability of RCT effects?
|
|
7
|
260
|
April 7, 2024
|
|
Immortal-time-bias vs. selection bias
|
|
2
|
232
|
April 7, 2024
|
|
RMS Describing, Resampling, Validating, and Simplifying the Model
|
|
158
|
39828
|
April 4, 2024
|
|
Run-in phase in RCTs
|
|
14
|
9664
|
April 1, 2024
|
|
Relationship between Probabilistic Index and Common Odds Ratio
|
|
1
|
128
|
April 1, 2024
|
|
RMS Titanic Binary Logistic Case Study
|
|
9
|
13717
|
March 28, 2024
|
|
Numerical Differences in Survival Probability Estimates between coxph and cph Functions
|
|
8
|
630
|
March 24, 2024
|
|
Individual response
|
|
236
|
34738
|
March 24, 2024
|
|
Redundancy analysis of covariates in a Cox model using flexible parametric additive models
|
|
9
|
533
|
March 22, 2024
|
|
Progression in cancer trials
|
|
25
|
3420
|
March 22, 2024
|
|
Validate and calibrate Cox model on dataset with a categorical covariate with few observations
|
|
2
|
230
|
March 21, 2024
|
|
Calculate incidence rate after adjustment
|
|
10
|
1311
|
March 19, 2024
|
|
Choosing variables for mutivariable survival prediction
|
|
21
|
3743
|
March 18, 2024
|
|
Executable Specification of Dose Escalation Oncology Protocol now on Arxiv
|
|
2
|
208
|
March 16, 2024
|
|
Bayesian vs. Frequentist Statements About Treatment Efficacy
|
|
0
|
1352
|
September 4, 2022
|
|
Model Performance with Repeat Predictions
|
|
10
|
288
|
March 12, 2024
|
|
External Validation and Calibration of Cox model
|
|
13
|
5162
|
March 12, 2024
|
|
Communicating statistical concerns to the FDA
|
|
3
|
385
|
March 11, 2024
|
|
Retrospective discussion on the ALS drug, RELYVRIO
|
|
0
|
266
|
March 10, 2024
|
|
Tresholds in bayesian designs
|
|
0
|
128
|
March 6, 2024
|